NVS Jan 2026 130.000 call
| Previous close | 2.1500 |
| Open | 2.1000 |
| Bid | 0.0000 |
| Ask | 5.0000 |
| Strike | 130.00 |
| Expiry date | 2026-01-16 |
| Day's range | 2.1000 - 2.1500 |
| Contract range | N/A |
| Volume | |
| Open interest | 9 |
GlobeNewswireNovartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio
In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction vs. placebo + supportive care at 36 weeks1Endothelin A (ETA) receptor activation contributes to elevated proteinuria in IgAN2-5; atrasentan is a potent, selective ETA receptor antagonist with potential to reduce persistent proteinuria and preserve kidney function for a broad patient population1 IgAN
PR NewswireNovartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
Novartis today presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G study of Fabhalta® (iptacopan) at the late-breaking clinical trials session of the European Renal Association (ERA) Congress1. Patients treated with Fabhalta in addition to supportive care achieved a 35.1% (p=0.0014) reduction in proteinuria (as measured by 24-hour urine protein to creatinine ratio [UPCR]) at 6 months when compared to placebo on top of supportive care1. In many kidney diseases, pro
ZacksWhy Cytokinetics (CYTK) Stock Price Was Down 17% on Thursday
Cytokinetics (CYTK) declines after announcing plans for raising about a billion dollars in funding.
